Therefore, neutralization of TNF-α could result in a mixed clinical response, similar to prior observations resulting from treatments targeting both receptors: inhibiting signaling of both TNFRI and TNFRII reduced collagen-induced arthritis, but increased pro-inflammatory cytokine levels and reduced Treg cell activity. The gene discussed is TNFRSF1A; the disease is Arthritis.